Table 2 The impact of HCV treatment modalities on HCC
Parameters | Post-IFN n = 30 | Post-DAAs n = 123 | No treatment n = 68 | p value |
|---|---|---|---|---|
Age (n= 221) | ||||
 Mean ± SD | 59.23 ± 6.44 | 57.25 ± 8.33 | 58.73 ± 9.75 | 0.2 |
 Median | 59.00 | 57.00 | 60.00 | |
Gender (n= 221) | ||||
 Male | 24 (80.0%) | 103 (83.7%) | 54 (79.4%) | 0.727 |
 Female | 6 (20.0%) | 20 (16.3%) | 14 (20.6%) | |
AFP (n= 162) | ||||
 < 200 ng/dl | 18 (66.7%) | 70 (79.5%) | 34 (72.3%) | 0.340 |
 ≥ 200 ng/dl | 9 (33.3%) | 18 (20.5%) | 13 (27.7%) | |
Tumor focality (n= 220) | ||||
 Solitary | 27 (90.0%) | 83 (68.0%) | 46 (67.6%) | 0.046 |
 Multiple | 3 (10.0%) | 39 (32.0%) | 22 (32.4%) | |
Tumor size (n= 221) | ||||
 Mean ± SD | 5.89 ± 3.30 | 5.59 ± 3.53 | 5.26 ± 2.89 | 0.63 |
 Median | 4.50 | 4.00 | 4.50 | |
Pathological grade (n= 203) | ||||
 I | 1 (3.6%) | 10 (8.8%) | 4 (6.6%) | 0.779 |
 II | 20 (71.4%) | 83 (72.8%) | 47 (77.0%) | |
 III | 7 (25.0%) | 21 (18.4%) | 10 (16.4%) | |
Tumor necrosis (n= 221) | ||||
 Mean ± SD | 8.50 ± 17.96 | 12.56 ± 22.81 | 3.82 ± 10.72 | 0.02 |
Pathological stage (n= 173) | ||||
 Early stage | 24 (92.3%) | 76 (81.7%) | 45 (83.3%) | 0.173 |
 Late stage | 2 (7.7%) | 17 (18.3%) | 9 (16.7%) | |
LVI (n= 177) | ||||
 Negative | 16 (59.3%) | 50 (52.1%) | 25 (46.3%) | 0.536 |
 Positive | 11 (40.7%) | 46 (47.9%) | 29 (53.7%) | |
Non-tumor liver (n= 217) | ||||
 Cirrhosis | 23 (79.3%) | 86 (70.5%) | 40 (60.6%) | 0.157 |
 Non-cirrhosis | 6 (20.7%) | 36 (29.5%) | 26 (39.4%) | |
Non-tumor inflammatory activity (n= 171) | ||||
 Mild | 12 (44.4%) | 38 (42.7%) | 29 (52.7%) | 0.796 |
 Moderate | 14 (51.9%) | 47 (52.8%) | 23 (41.8%) | |
 Marked | 1 (3.7%) | 4 (4.5% | 3 (5.5%) | |